menuBe part of the knowledge.™
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Upcoming Events

Advances in the Treatment and Management of MASH: More Options, More Decisions

Join us at ACG 2024 to learn about best practices for applying advances in MASLD/MASH diagnosis, treatment, and management.

Live Meeting
1.50 available credits
Information
October 26, 2024
07:30 PM - 09:30 PM ET
Philadelphia Marriott Downtown
1200 Filbert St, Room: Salon ABF (Level 5), Philadelphia, Pennsylvania, United States
ReachMD Healthcare Image
Details
Presenters
Comments

  • Overview

    MASLD/MASH is a serious and progressive chronic disease. It is a major driver of the development of liver cancer and will soon be the most common indication for liver transplantation. The good news is that we now have a better appreciation of the need to modify cardiometabolic pathways in these patients, and the treatment landscape is evolving with the recent FDA approval of a liver-directed therapy. It is therefore imperative that gastroenterologists and advanced practice providers stay on the cutting edge of ongoing innovations to stem the tide of the MASLD/MASH epidemic and its consequences. This symposium will help you fine-tune your practice by providing practical, interactive discussions of early identification and risk stratification, advances in treatment, monitoring for disease progression, and long-term medical management.

    This event is neither sponsored by nor endorsed by ACG. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.  

    Host: 
    Michael R. Charlton, MBBS 
    Professor of Medicine
    Co-Director, Transplant Institute
    The University of Chicago
    Chicago, IL 

    Dr. Charlton has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: 89Bio, Akero, Alnylam, Amgen, AMRA, BMS, Boehringer Ingelheim, Enanta, Fractyl, Galecto, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Sagimet, Siemens, Terns, Theratechnologies, Thetis, Rivus 

    Faculty: 
    Naga Chalasani, MD, FACG 
    David W. Crabb Professor of Gastroenterology and Hepatology
    Indiana University School of Medicine
    Vice President for Academic Affairs
    Indiana University Health
    Indianapolis, IN 

    Dr. Chalasani has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Akero, Altimmune, BioMed, GSK, Ipsen, Madrigal Pharmaceuticals, Merck, Pfizer, Zydus
    Ownership Interest: Avant Santé, Heligenics
    Research: Boehringer Ingelheim, Exact Sciences  

    Mary E. Rinella, MD 
    Professor of Medicine 
    Director, Metabolic and Fatty Liver Disease
    University of Chicago Medicine
    Chicago, IL 

    Dr. Rinella has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Boehringer Ingelheim, CytoDyn, GSK, HistoIndex, Incyte, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Novo Nordisk, Sonic, Takeda 

    Reviewers/Content Planners/Authors: 

    • Cindy Davidson has nothing to disclose.  
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose. 
    • Susan Smith, MN, PhD, has ownership interest in Hepion Pharmaceuticals. 
    • Rosanne Strauss, PharmD, has nothing to disclose. 

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Demonstrate best practices for follow-up of patients with risk factors for metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH)  
    • Take the appropriate action in a patient with risk factors for MASLD/MASH and a given risk stratification score  
    • Select an appropriate treatment strategy for a patient with cardiometabolic risk factors who is also at risk for clinically significant hepatic fibrosis   
    • Interpret data from phase 3 clinical trials of novel therapies being investigated for the treatment of MASLD/MASH  

  • Target Audience

    This activity is designed to meet the educational needs of gastroenterologists and hepatologists, as well as physicians, nurses, physician assistants, nurse practitioners, pharmacists, and all other healthcare providers involved in managing patients with chronic liver disease.  

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.  

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

    Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.  

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.   

    Global Learning Collaborative (GLC) designates this activity for 1.5 contact hours/0.15 CEUs of pharmacy contact hours.  
     
    The Universal Activity Number for this program is JA0006235-0000-24-070-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net) 

  • Provider(s)/Educational Partner(s)


    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.      

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.   

  • Commercial Support

    This activity is supported by an independent educational grant from Madrigal Pharmaceuticals. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited 
    Reproduction of this materialis not permitted without written permission from the copyright owner. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Details
Presenters
Comments
Recommended

  • Overview

    MASLD/MASH is a serious and progressive chronic disease. It is a major driver of the development of liver cancer and will soon be the most common indication for liver transplantation. The good news is that we now have a better appreciation of the need to modify cardiometabolic pathways in these patients, and the treatment landscape is evolving with the recent FDA approval of a liver-directed therapy. It is therefore imperative that gastroenterologists and advanced practice providers stay on the cutting edge of ongoing innovations to stem the tide of the MASLD/MASH epidemic and its consequences. This symposium will help you fine-tune your practice by providing practical, interactive discussions of early identification and risk stratification, advances in treatment, monitoring for disease progression, and long-term medical management.

    This event is neither sponsored by nor endorsed by ACG. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.  

    Host: 
    Michael R. Charlton, MBBS 
    Professor of Medicine
    Co-Director, Transplant Institute
    The University of Chicago
    Chicago, IL 

    Dr. Charlton has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: 89Bio, Akero, Alnylam, Amgen, AMRA, BMS, Boehringer Ingelheim, Enanta, Fractyl, Galecto, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Sagimet, Siemens, Terns, Theratechnologies, Thetis, Rivus 

    Faculty: 
    Naga Chalasani, MD, FACG 
    David W. Crabb Professor of Gastroenterology and Hepatology
    Indiana University School of Medicine
    Vice President for Academic Affairs
    Indiana University Health
    Indianapolis, IN 

    Dr. Chalasani has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Akero, Altimmune, BioMed, GSK, Ipsen, Madrigal Pharmaceuticals, Merck, Pfizer, Zydus
    Ownership Interest: Avant Santé, Heligenics
    Research: Boehringer Ingelheim, Exact Sciences  

    Mary E. Rinella, MD 
    Professor of Medicine 
    Director, Metabolic and Fatty Liver Disease
    University of Chicago Medicine
    Chicago, IL 

    Dr. Rinella has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Boehringer Ingelheim, CytoDyn, GSK, HistoIndex, Incyte, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Novo Nordisk, Sonic, Takeda 

    Reviewers/Content Planners/Authors: 

    • Cindy Davidson has nothing to disclose.  
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose. 
    • Susan Smith, MN, PhD, has ownership interest in Hepion Pharmaceuticals. 
    • Rosanne Strauss, PharmD, has nothing to disclose. 

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Demonstrate best practices for follow-up of patients with risk factors for metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH)  
    • Take the appropriate action in a patient with risk factors for MASLD/MASH and a given risk stratification score  
    • Select an appropriate treatment strategy for a patient with cardiometabolic risk factors who is also at risk for clinically significant hepatic fibrosis   
    • Interpret data from phase 3 clinical trials of novel therapies being investigated for the treatment of MASLD/MASH  

  • Target Audience

    This activity is designed to meet the educational needs of gastroenterologists and hepatologists, as well as physicians, nurses, physician assistants, nurse practitioners, pharmacists, and all other healthcare providers involved in managing patients with chronic liver disease.  

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.  

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

    Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.  

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.   

    Global Learning Collaborative (GLC) designates this activity for 1.5 contact hours/0.15 CEUs of pharmacy contact hours.  
     
    The Universal Activity Number for this program is JA0006235-0000-24-070-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net) 

  • Provider(s)/Educational Partner(s)


    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.      

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.   

  • Commercial Support

    This activity is supported by an independent educational grant from Madrigal Pharmaceuticals. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited 
    Reproduction of this materialis not permitted without written permission from the copyright owner. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Recommended

Schedule31 Aug 2024
PrevNext

Program Chapters

Segment Chapters

Playlist:

Recommended